- US12594343utility2026Treatment of Cancer0 cites
- US12528876utility2026CD73 Blocking Antibodies0 cites
- US12448442utility2025Treatment of T Cell Lymphoma0 cites
- US12365731utility2025Nkp46 Binding Agents0 cites
- US12252543utility2025Multispecific NK Engager Protein0 cites
- US12227569utility2025Humanized Antibodies with Increased Stability0 cites
- US12209126utility2025Treatment of Cancer0 cites
- US12084498utility2024Compound That Specifically Binds to KIR3DL2 for Use in the Treatment of Peripheral T Cell Lymphoma0 cites
- US12037392utility2024Treatment Regimens Using Anti-nkg2a Antibodies0 cites
- US11999784utility2024Treatment of Peripheral T Cell Lymphoma0 cites
- US11970535utility2024Treatment with Anti-kir3dl2 Agents0 cites
- US11958907utility2024CD73 Blockade0 cites
- US11891444utility2024Variable Regions for Nkp46 Binding Proteins0 cites
- US11858990utility2024KIR3DL2 Binding Agents0 cites
- US11845795utility2023Nkp46 Binding Proteins0 cites
- US11795222utility2023Treatment of Head and Neck Cancer0 cites
- US11623954utility2023Siglec-9-neutralizing Antibodies0 cites
- US11572410utility2023Neutralization of Inhibitory Pathways in Lymphocytes0 cites